AKTX vs CTSH · $17.2M cap vs P/E 12, rev $21.11B
Akari Therapeutics PLC (AKTX) versus Cognizant Technology Solutions Corp Class A (CTSH) — a side-by-side from cached financials, not a winner call.
Akari Therapeutics PLC (AKTX) is a biotechnology company listed on US.
Cognizant Technology Solutions Corp Class A (CTSH) is a information technology services company listed on US.
AKTX does not have a complete income-statement cache yet.
Latest reported CTSH revenue for 2025-12-31 was $21.11B. Net income was $2.23B. Revenue was up 7.0% from 2024-12-31 to 2025-12-31. CTSH currently screens at market cap $25.17B and trailing P/E 11.5.
AKTX currently screens at market cap $17.2M. CTSH currently screens at market cap $25.17B and trailing P/E 11.5.
Not investment advice. Open the AKTX and CTSH stock pages for the full models.
Not investment advice.